- Retrospective Study Finds That Masimo SET® Pulse Oximetry Has No Difference in Accuracy or Bias Between Black People and White People
- Masimo Announces Select Preliminary Full-Year 2021 Financial Results and 2022 Guidance
- New Study Suggests That Masimo SedLine® Brain Function Monitoring May Aid Early Identification of Patients at Risk of Developing Postoperative Delirium
- Masimo Rad-G® Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in India
- MDoloris Medical Systems Announces the Regulatory Clearance and the Upcoming Launch of its Analgesia Nociception Index Platform in Japan with Heiwa Bussan
- Masimo to Present in Piper Sandler 33rd Annual Healthcare Conference
- New Study Finds That Use of Masimo SedLine® PSi and DSA May Significantly Reduce Postoperative Delirium
- Masimo to Present in Stifel 2021 Virtual Healthcare Conference
- Masimo Root® with a Multimodal Brain Monitoring Algorithm May Improve Postoperative Neurocognition in Elderly Patients
- Masimo Launches Dual SET® Pulse Oximetry
Masimo Corp (3M4:STU) closed at 197.55, 17.48% above the 52 week low of 168.15 set on Jun 08, 2021.
168.15Jun 08 2021269.50Nov 19 2021
Markit short selling activity
|Market cap||11.76bn USD|
|EPS (TTM)||4.02 |
Data delayed at least 15 minutes, as of Jan 25 2022.